Literature DB >> 22986542

[HIV infection : chronic disease with comorbidities].

J R Bogner1.   

Abstract

While HIV therapy is highly efficient comorbidities come into the focus of HIV long-term treatment and prognosis. The pathogenesis of many comorbid diseases is determined not only by the biological effects of the HIV infection itself but also by lifestyle and long-term adverse reactions of antiviral treatment. The HIV specialist should nowadays be an all-round internist or needs a good infrastructure of cooperation. Cardiovascular risk factors in HIV infection include serum lipids, especially high LDL levels under antiviral treatment. They can be managed either by a switch of HIV therapy of by the addition of lipid-lowering agents. However, smoking habits and normalization of high blood pressure are also of importance. Further important comorbidities present in patients are viral hepatitis B or C, nephropathy (HIV or secondary) and changes of bone turnover resulting in lower bone mass and stability. Other aspects include vaccination status and prevention also for non-HIV associated carcinomas.

Entities:  

Mesh:

Year:  2012        PMID: 22986542     DOI: 10.1007/s00108-011-2972-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  34 in total

1.  Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.

Authors:  R K Walli; G M Michl; J R Bogner; F D Goebel
Journal:  Eur J Med Res       Date:  2001-10-29       Impact factor: 2.175

Review 2.  Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

Authors:  Susanna Naggie; Mark S Sulkowski
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 3.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Authors:  A Carr; K Samaras; D J Chisholm; D A Cooper
Journal:  Lancet       Date:  1998-06-20       Impact factor: 79.321

4.  Sterol regulatory element-binding protein 2 couples HIV-1 transcription to cholesterol homeostasis and T cell activation.

Authors:  Harry E Taylor; Michael E Linde; Atanu K Khatua; Waldemar Popik; James E K Hildreth
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

Review 5.  Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.

Authors:  Absalon D Gutierrez; Ashok Balasubramanyam
Journal:  Endocrine       Date:  2011-12-02       Impact factor: 3.633

Review 6.  HIV infection and bone disease: implications for an aging population.

Authors:  Aoife G Cotter; Patrick W G Mallon
Journal:  Sex Health       Date:  2011-12       Impact factor: 2.706

7.  Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia.

Authors:  Ana Barrios; Francisco Blanco; Teresa García-Benayas; José Manuel Gómez-Viera; Juan José de la Cruz; Vincent Soriano; Juan González-Lahoz
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

8.  Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

Authors:  C Cohen; L Nieto-Cisneros; C Zala; W J Fessel; J Gonzalez-Garcia; A Gladysz; R McGovern; E Adler; C McLaren
Journal:  Curr Med Res Opin       Date:  2005-10       Impact factor: 2.580

Review 9.  Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.

Authors:  Pedro E Cahn; José M Gatell; Kathleen Squires; Lisa D Percival; Peter J Piliero; Ian A Sanne; Sarah Shelton; Adriano Lazzarin; Linda Odeshoo; Thomas D Kelleher; Alexandra Thiry; Michael D Giordano; Stephen M Schnittman
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2004 Jul-Sep

10.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

Authors:  R Walli; O Herfort; G M Michl; T Demant; H Jäger; C Dieterle; J R Bogner; R Landgraf; F D Goebel
Journal:  AIDS       Date:  1998-10-22       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.